Biotechnology Stocks

Biotechnology stocks are firms that are active in the sector and publicly traded. Biotechnology companies use applied biology for advancements in current methodologies in a variety of industries. The field uses living organisms and bio-processes in many sectors, such as medicine, engineering, agriculture and technology. Since there is a lot of research and development in this sector, small biotech stocks that can develop a new advancement in technology can become very wealthy firms and the stock price can move up sharply. Biotechnology stocks raise money in the public market to help fund this research.


Biotech Stocks to Watch for 100%+ Gains In 2016 A tweet from Hillary Clinton last Monday announcing forthcoming proposals to halt escalating drug prices caused biotech stocks to fall on Wall Street. The NASDAQ Biotech Index fell more than five…

Before Black Friday, the biotech industry was seriously outperforming the S&P 500. In fact, aside from a solid correction in early 2014 (which it subsequently topped a few months later), the biotech sector has been one of the bright spots…

The best biotech stocks to watch for in May 2015 are businesses that dominate their respective market, command a diverse drug pipeline, and have lots of profits to show for it. Profitability is crucial given that the NASDAQ Biotechnology Index…

The main market indices remain in consolidation, with the more speculative averages like the Russell 2000 and NASDAQ Biotechnology Index now experiencing a bit of a price retrenchment. However, biotech stocks are still the place to be if you’re looking…

With indecisive stock market action, biotechnology stocks continue to show their speculative strength. It’s a market sector that continues to be very strong, albeit highly speculative. Of course, where there’s growth, there are also higher valuations and many of the…

One of the hottest areas of the stock market over the last few years has been one of its most speculative. Biotechnology stocks, as evidenced by the NASDAQ Biotechnology Index, have been on a tear for the last three years.…

One of the problems with pure-play biotechnology stocks is that they are 100% risk-capital securities in which the probability of success is entirely beyond your control. But healthcare and related industry investments are very much worthwhile in an equity market…

The stock market has an underlying strength to it, seemingly only to be undone by geopolitical events. Fed action always has the potential to shock the system. Negative economic news isn’t fazing this market. On the back of a pretty…

Biotechnology stocks and the Russell 2000 began rolling over at the beginning of July, followed by transportation stocks at the end of the month. It’s definitely a signal that the stock market is tired, but after such a strong breakout…

In what is on par with the course in today’s stock market, biotechnology firm Amgen Inc. (AMGN) posted double-digit revenue and earnings growth while raising its full-year outlook. The kicker for this stock and its recent price strength was the…

Everything in the stock market experiences its own cycle of enthusiasm among investors. And this is especially well illustrated among speculative issues. There was a time only a few years ago when some of the hottest speculative stocks were in…

One of the most speculative parts of the equity market is biotechnology. These stocks come to market generally overpriced, and they usually require a lot more capital to develop anything material. But while investment risk is super high with these…

If there’s been a rotation into safer, more reasonably priced stocks, the trend can also reverse itself when the market is ready. Biotechnology stocks, initial public offerings (IPOs), and hyper-priced technology issues were ripe for a sell-off after such tremendous…

Two years ago, when the former Kraft Foods Inc. broke itself up, spinning off its global food and beverage business (now Kraft Foods Group, Inc. [KRFT]), the company renamed itself Mondelez International, Inc. (MDLZ). Now, the company is mostly a…

If business conditions are good for a public company, then it’s highly likely that its share price has already been doing well in this great monetary expansion. With the stock market at a high, it’s tricky being a new buyer/speculator.…

Being financial reporting season, it’s important to discern between results that beat Wall Street consensus and real economic growth. Abbott Laboratories (ABT) just announced better-than-expected first-quarter earnings, but they weren’t better than the comparable quarter of 2013. Operating earnings, earnings…

Trading action in stocks has been all over the map so far this year, while investor sentiment remained generally positive. The fact that there was a bunch of profit-taking after the solid recovery in February and March is neither a…